Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 8/2009

01-12-2009 | Research Paper

Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients

Authors: Fangwei Xie, Kun Li, Xuenong Ouyang

Published in: Clinical & Experimental Metastasis | Issue 8/2009

Login to get access

Abstract

The transcription factor Twist plays a key role in cancer metastasis. The present study aimed at investigating clinical Twist expression in patients with esophageal squamous cell carcinoma (ESCC) in order to correlate the Twist levels with the patients’ survival rates and their other clinical parameters. Immunohistochemical staining using polyclonal Twist antibody was performed on paraffin embedded specimens of 112 ESCC patients and non-neoplastic esophageal epithelium used as a control. The overall staining intensity was analyzed along with clinicopathologic data and prognosis of ESCC. Twist expression was significantly higher in ESCC than in non-neoplastic oesophageal epithelium (P < 0.001). The Twist expression directly correlated with distant metastasis after esophagectomy (P = 0.001). Kaplan–Meier estimate in conjunction with the log-rank test revealed an inverse proportion relationship between postoperative survival rates of the patients and their Twist expression levels (log-rank, P < 0.001). In addition, Cox mono-variate analysis revealed that T/N classification, pTNM stage, distant metastasis and Twist expression were significantly correlated with mortality risk of patients after operation (P < 0.05). By Cox multi-variate analysis, Twist expression (risk ratio = 2.394; P < 0.001) and N classification were identified as the independent prognostic factors of patient survival. In conclusion, upregulated Twist expression in the primary ESCC significantly correlates with the high risk of subsequent development of distant metastasis and low postoperative survival rates; the latter was not significantly correlated with patients’ age, gender, tumor location and differentiation. Twist may serve as an independent prognostic marker for predicting development of distant metastasis in ESCC patients and their survival.
Literature
1.
Jemal A, Thun MJ, Ries LAG et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694CrossRefPubMed
2.
Wingo PA, Ries LA, Rosenberg HM et al (1998) Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 82:1197–1207CrossRefPubMed
3.
Fleming ID, Cooper JS, Henson DE et al (2002) AJCC Cancer staging manual. Lippincott-Raven, Philadelphia
4.
Ikeda M, Natsugoe S, Ueno S et al (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238:197–202PubMed
5.
Noguchi T, Kimura Y, Takeno S et al (2003) Chromosomal imbalance in esophageal squamous cell carcinoma: 3q gain correlates with tumor progression but not prognostic significance. Oncol Rep 10:1393–1400PubMed
6.
Tabernero J, Macarulla T, Ramos FJ et al (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740–1748CrossRefPubMed
7.
8.
Thisse B, Stoetzel C, El Messal M et al (1987) The Twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorso-ventral pattern. Nucleic Acids Res 15:3439–3453CrossRefPubMed
9.
Hüsemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68CrossRefPubMed
10.
Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMed
11.
Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66:4549–4552CrossRefPubMed
12.
Yuen HF, Chan YP, Wong ML et al (2007) Upregulation of Twist in esophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 60:510–514CrossRefPubMed
13.
Kajiyama H, Hosono S, Terauchi M et al (2006) Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology 71:394–401CrossRefPubMed
14.
Lee TK, Poon RT, Yuen AP et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369–5376CrossRefPubMed
15.
Song LB, Liao WT, Mai HQ et al (2006) The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 242:258–265CrossRefPubMed
16.
He P, Shi J, Chen W et al (2002) Multivariate analysis by Cox Proportional Hazards Model on prognoses of patients with bile duct carcinoma after resection. Chin Med J 115:1538–1541PubMed
17.
Hamilton SR, Aaltonen LA (2000) World Health Organization classification of tumors. Pathology and genetics of tumors of the digestive system. IARC Press, Lyon
18.
Cox DR (1972) Regression models and life tables. J R Stat Soc Ser B 34:187–220
19.
Zhang Z, Xie D, Li X et al (2007) Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38:598–606CrossRefPubMed
20.
Puisieux A, Valsesia-Wittmann S, Ansieau S (2006) A Twist for survival and cancer progression. Br J Cancer 94:13–17CrossRefPubMed
21.
22.
Podsypanina K, Du YN, Jechlinger M et al (2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321:1841–1844CrossRefPubMed
23.
Ansieau S, Bastid J, Doreau A et al (2008) Induction of EMT by Twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14:79–89CrossRefPubMed
24.
Hoek K, Rimm DL, Williams KR et al (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270–5282CrossRefPubMed
25.
Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939CrossRefPubMed
26.
Weinberg RA (2008) Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 14:283–284CrossRefPubMed
Metadata
Title
Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients
Authors
Fangwei Xie
Kun Li
Xuenong Ouyang
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 8/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9292-5

Other articles of this Issue 8/2009

Clinical & Experimental Metastasis 8/2009 Go to the issue

Research Paper

Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts

Research Paper

Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples

Research Paper

Osteoblasts modulate Ca2+ signaling in bone-metastatic prostate and breast cancer cells

Research Paper

MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection

Research Paper

Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis

Research Paper

Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits